JP7769404B2 - インターロイキン－１受容体関連キナーゼ１及び４の阻害剤 - Google Patents

インターロイキン－１受容体関連キナーゼ１及び４の阻害剤

Info

Publication number
JP7769404B2
JP7769404B2 JP2023504544A JP2023504544A JP7769404B2 JP 7769404 B2 JP7769404 B2 JP 7769404B2 JP 2023504544 A JP2023504544 A JP 2023504544A JP 2023504544 A JP2023504544 A JP 2023504544A JP 7769404 B2 JP7769404 B2 JP 7769404B2
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
acid
pharmaceutically acceptable
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023504544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535725A5 (https=
JP2023535725A (ja
Inventor
ベッカー，マイケル
シング，ラケシュ
ムーア，リチャード
カルヴィ，ローラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of JP2023535725A publication Critical patent/JP2023535725A/ja
Publication of JP2023535725A5 publication Critical patent/JP2023535725A5/ja
Application granted granted Critical
Publication of JP7769404B2 publication Critical patent/JP7769404B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023504544A 2020-07-24 2021-07-23 インターロイキン－１受容体関連キナーゼ１及び４の阻害剤 Active JP7769404B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055970P 2020-07-24 2020-07-24
US63/055,970 2020-07-24
PCT/US2021/042874 WO2022020661A1 (en) 2020-07-24 2021-07-23 Inhibitors of interleukin-1 receptor-associated kinases 1 and 4

Publications (3)

Publication Number Publication Date
JP2023535725A JP2023535725A (ja) 2023-08-21
JP2023535725A5 JP2023535725A5 (https=) 2024-07-22
JP7769404B2 true JP7769404B2 (ja) 2025-11-13

Family

ID=77338897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504544A Active JP7769404B2 (ja) 2020-07-24 2021-07-23 インターロイキン－１受容体関連キナーゼ１及び４の阻害剤

Country Status (7)

Country Link
US (1) US20230295146A1 (https=)
EP (1) EP4185568A1 (https=)
JP (1) JP7769404B2 (https=)
CN (1) CN116057051B (https=)
AU (1) AU2021311811A1 (https=)
CA (1) CA3186896A1 (https=)
WO (1) WO2022020661A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011043371A1 (ja) 2009-10-07 2011-04-14 アステラス製薬株式会社 オキサゾール化合物
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
WO2019006126A1 (en) 2017-06-29 2019-01-03 Rigel Pharmaceuticals, Inc. KINASE INHIBITORS AND METHODS OF MAKING AND USING THEM
JP2019535759A (ja) 2016-11-22 2019-12-12 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド インターロイキン１受容体関連キナーゼの阻害剤およびその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR900482A (fr) 1942-12-17 1945-06-29 Fides Gmbh Condensateur électrostatique avec diélectrique consistant au moins partiellement en produits de transformation non conducteurs d'une armature
FR66979E (fr) 1953-06-22 1957-11-04 Glaenzer Spicer Sa Support pour arbre rotatif
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
ES2422263T3 (es) * 2008-12-19 2013-09-10 Nerviano Medical Sciences Srl Pirazoles bicíclicos como inhibidores de la proteinquinasa
US8987275B2 (en) * 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
RU2730016C2 (ru) * 2015-02-05 2020-08-14 Мерк Патент Гмбх Макроциклические соединения в качестве irak1/4 ингибиторов и их применение
EP3642201A1 (en) * 2017-06-21 2020-04-29 H. Hoffnabb-La Roche Ag Isoindolinone derivatives as irak4 modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011043371A1 (ja) 2009-10-07 2011-04-14 アステラス製薬株式会社 オキサゾール化合物
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
JP2019535759A (ja) 2016-11-22 2019-12-12 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド インターロイキン１受容体関連キナーゼの阻害剤およびその使用
WO2019006126A1 (en) 2017-06-29 2019-01-03 Rigel Pharmaceuticals, Inc. KINASE INHIBITORS AND METHODS OF MAKING AND USING THEM

Also Published As

Publication number Publication date
EP4185568A1 (en) 2023-05-31
WO2022020661A1 (en) 2022-01-27
AU2021311811A1 (en) 2023-03-02
JP2023535725A (ja) 2023-08-21
CA3186896A1 (en) 2022-01-27
US20230295146A1 (en) 2023-09-21
CN116057051A (zh) 2023-05-02
CN116057051B (zh) 2025-09-23

Similar Documents

Publication Publication Date Title
EP3704125B1 (en) Modulators of the integrated stress pathway
AU2022203703A1 (en) Compositions and methods for inhibiting arginase activity
EP3041828B1 (en) 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
US20240000792A1 (en) Modulators of the integrated stress pathway
EP3938038A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
US20250122160A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
EP2647622B1 (en) Kinesin spindle protein inhibitors and application thereof
CA3080804A1 (en) Modulators of the integrated stress pathway
AU2018360847A1 (en) Modulators of the integrated stress pathway
JP2020531531A (ja) アデノシン受容体アンタゴニストとしてのベンズイミダゾール誘導体
JP2016531163A (ja) Ｈｄａｃ６阻害物質を用いた、異常なリンパ球の機能に起因する疾患の治療
JP2020531526A (ja) アデノシン受容体アンタゴニストとしてのキノキサリン誘導体
JP7769404B2 (ja) インターロイキン－１受容体関連キナーゼ１及び４の阻害剤
JP7812571B2 (ja) ヒト精巣上体タンパク質４の阻害剤
JP7062010B2 (ja) ３－（１－オキソ－４－（（４－（（３－オキソモルホリノ）メチル）ベンジル）オキシ）イソインドリン－２－イル）ピペリジン－２，６－ジオン及びそのアイソトポログ
CA3109778A1 (en) Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
US20140357865A1 (en) Process for the Preparation of Benzoimidazol-2-yl Pyrimidine Derivatives
RU2781429C2 (ru) Бензимидазольные производные в качестве антагонистов аденозиновых рецепторов
WO2025217096A1 (en) Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
CN121969627A (zh) 氟烷氧基亚烷基-二氢咪唑并[5,1-d]四嗪酮化合物和相关的化合物及其在治疗医学疾病中的用途
HK1227019B (en) 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240711

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251024

R150 Certificate of patent or registration of utility model

Ref document number: 7769404

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150